Pacira BioSciences, Inc. (PCRX)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$26.35-0.94%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · PCRX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 746.2 | 726.4 | — | 675.0 | 666.8 | 541.5 | 429.6 | 421.0 | 337.3 | 286.6 | 276.4 | 249.0 | 197.7 | 85.6 | 39.1 | 15.7 |
| Total Revenues | — | — | — | — | — | 541.5 | 429.6 | 421.0 | 337.3 | 286.6 | 276.4 | 249.0 | 197.7 | 85.6 | 39.1 | 15.7 |
| Cost of Revenues | 155.2 | 149.7 | 170.4 | 184.7 | 199.3 | 140.3 | 117.3 | 106.7 | 86.8 | 87.9 | 110.1 | 71.8 | 77.4 | 54.8 | 32.1 | 16.7 |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 379.2 | 368.8 | 294.1 | 269.4 | 254.5 | 199.3 | 193.5 | 200.8 | 177.3 | 161.5 | 152.6 | 139.0 | 106.7 | 62.5 | 46.3 | 20.2 |
| R&D Expenses | 122.1 | 117.3 | 81.6 | 76.3 | 84.8 | 55.5 | 59.4 | 72.1 | 55.7 | 57.3 | 45.7 | 28.7 | 18.7 | 21.6 | 9.9 | 14.9 |
| Operating Income | 19.9 | 19.2 | (73.4) | 87.7 | 60.0 | 89.9 | 46.4 | 10.5 | 15.9 | (24.9) | (32.0) | 9.5 | (5.2) | (53.3) | (49.3) | (39.1) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | 17.4 | 16.6 | 20.3 | 40.0 | 31.8 | 25.7 | 23.6 | 21.9 | 18.0 | 7.1 | 7.7 | 8.3 | 7.3 | 1.8 | 4.8 |
| Interest & Investment Income | 14.7 | 22.7 | 19.7 | 11.4 | 4.5 | 0.9 | 4.6 | 7.4 | 6.5 | 4.1 | 1.3 | 0.7 | 0.4 | 0.3 | 0.3 | 0.3 |
| Net Interest Expenses | — | — | — | 8.9 | 35.4 | 30.9 | 21.0 | 16.3 | 15.5 | 14.0 | 5.7 | 7.0 | 7.9 | 7.0 | 1.5 | 4.5 |
| Other Non-Operating Income / Expenses | (2.2) | (2.3) | — | (26.0) | (46.7) | (33.5) | (26.3) | (21.2) | (16.3) | (17.5) | (5.8) | (7.3) | (8.4) | (11.1) | (3.0) | (4.2) |
| EBT, Incl. Unusual Items | 17.6 | 16.9 | (63.1) | 61.7 | 13.3 | 56.4 | 20.1 | (10.7) | (0.4) | (42.5) | (37.8) | 2.1 | (13.5) | (64.4) | — | — |
| Income Tax Expense | 3.0 | 9.8 | 36.5 | 19.7 | (2.6) | 14.4 | (125.4) | 0.3 | 0.0 | 0.1 | 0.1 | 0.3 | 0.2 | (0.4) | — | — |
| Net Income | ||||||||||||||||
| Net Income | 14.6 | 7.0 | (99.6) | 42.0 | 15.9 | 42.0 | 145.5 | (11.0) | (0.5) | (42.6) | (37.9) | 1.9 | (13.7) | (63.9) | (52.3) | (43.3) |
| Per Share | ||||||||||||||||
| Basic EPS | 0.37 | 0.16 | (2.15) | 0.91 | 0.35 | 0.95 | 3.41 | — | — | (1.07) | (1.02) | 0.05 | — | — | — | — |
| Diluted EPS | 0.36 | 0.16 | (2.15) | 0.89 | 0.34 | 0.92 | 3.33 | — | — | (1.07) | (1.02) | 0.04 | — | — | — | — |
| Revenue per Share | 18.52 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 39.5 | 44.6 | 46.2 | 46.2 | 45.5 | 44.3 | 42.7 | — | 40.9 | 39.8 | 37.2 | 36.5 | 35.3 | 33.2 | 30.3 | 16.4 |
| Diluted Weighted Avg Shares | 40.3 | 45.0 | 46.2 | 52.0 | 46.5 | 45.6 | 43.7 | 41.5 | — | 39.8 | 37.2 | 41.3 | — | — | — | 16.4 |
| Supplemental | ||||||||||||||||
| EBITDA | — | 110.2 | 5.4 | 163.2 | 151.5 | 118.5 | 66.3 | 30.1 | 29.1 | (11.1) | (19.1) | 20.9 | 4.9 | (47.5) | (43.7) | (34.8) |
| EBIT | 19.9 | 19.2 | (73.4) | 87.7 | 60.0 | 89.9 | 46.4 | 10.5 | 15.9 | (24.9) | (32.0) | 9.5 | (5.2) | (53.3) | (49.3) | (39.1) |
| Effective Tax Rate | 17.1% | — | — | 32.0% | -19.6% | 25.6% | -624.4% | -2.5% | -10.8% | -0.3% | -0.3% | 12.5% | -1.3% | 0.7% | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.